Canaccord raised the firm’s price target on Guardant Health (GH) to $65 from $60 and keeps a Buy rating on the shares. The firm said they remain bullish following strong execution to start 2025 and raised their price target given increased estimates. They believe the shares remain undervalued due to Guardant’s established therapy selection business and progress in minimal residual disease and screening.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health’s Strong Growth Potential and Upward Trajectory Justifies Buy Rating
- Guardant Health: Strong Financial Performance and Growth Potential Justify Buy Rating
- Guardant Health: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- Guardant Health price target raised to $60 from $55 at Barclays
- Guardant Health Reports Strong Q1 2025 Growth